Diagnoptics News

What's new?

Read all news items about the AGE Reader, Diab-spot and DiagnOptics.

New patent granted to Diagnoptics in Japan and EU.

Groningen, the Netherlands – January 7, 2016

Diagnoptics announces that it has been granted a Japan and EU patent for a method for skin colour independent assessment of Advanced Glycation Endproducts 

A method for skin colour independent assessment of skin Advanced Glycation Endproducts (by measuring autofluorescence) is essential in the international introduction of the AGE Reader technology. It allows Diagnoptics to protect its technological advances in non-invasively measuring tissue levels of Advanced Glycation Endproducts. The new patents reinforce that Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess cardiovascular risk and the risk of diabetes.

The AGE Reader provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader allows a Point-of-Care and non-invasive assessment of cardiovascular risk. The method is convenient, easy to use and validated. The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques (skin autofluorescence (skin AF)). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.

Diagnoptics was the first company worldwide to introduce a technology to non-invasively measure the tissue accumulation of AGEs by means of fluorescence techniques (AGE Reader). The AGE Reader has been used in clinical practice and research since 2006. Since the introduction of the AGE Reader over 140 peer reviewed scientific papers have been published.

Share this link on:

Latest news items

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.